Overview

Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SEL-302 in Pediatric Subjects With MMA

Status:
Recruiting

Trial end date:
2029-08-01

Target enrollment:

Participant gender:

Summary

This Phase 1/2 study will evaluate the safety and pharmacodynamics (PD) of SEL-302, which consists of the gene transfer vector MMA-101 following administration of an immunomodulatory SEL-110 agent in pediatric subjects with Methylmalonyl-CoA Mutase (MMUT) MMA.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Selecta Biosciences, Inc.

Collaborator:

National Human Genome Research Institute (NHGRI)